抗C型肝炎ウイルス（HCV）物質の同定及びHCVならびにデングワクチンの開発 C型肝炎・デング熱を克服する薬を 猛威を振るう2つの感染症に、科学技術協力で立ち向かう C型肝炎ウイルス（HCV）はワクチンが未開発で、慢性感染者は世界で1億7千万人と推定される ...

アイスランドが2016年2月に導入した、C型肝炎ウイルス（HCV）撲滅プログラムTraP HepCの3年間のケアカスケードを住民を対象とした研究で検証。TraP HepCでは、診断および治療へのアクセスを最大限に高めることを目的とし、啓発キャンペーン、検査へのアクセス ...

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

Atea Pharmaceuticals Inc (AVIR) showcases strong clinical progress and financial stability while navigating competitive challenges in the HCV treatment landscape.